Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bioxyne Limited ( (AU:BXN) ) just unveiled an announcement.
Bioxyne has upgraded its FY26 adjusted EBITDA guidance to a range of $16.5 million to $19.0 million, up from $11.5 million to $13.5 million, after a stronger than expected first half. The company delivered H1 FY26 adjusted EBITDA of $8.3 million, more than double the prior corresponding period, while revenue rose to $31.3 million and full-year revenue guidance remains unchanged at $65 million to $75 million.
Management attributes the earnings uplift to successful margin expansion initiatives and efficient scaling of the business rather than any change in topline expectations. The improved profitability signals stronger operational leverage in Bioxyne’s expanding pharmaceuticals and controlled substances portfolio, reinforcing its positioning in alternative therapeutics and supporting expectations for a robust full-year result for investors and other stakeholders.
The most recent analyst rating on (AU:BXN) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Bioxyne Limited stock, see the AU:BXN Stock Forecast page.
More about Bioxyne Limited
Bioxyne Limited is an Australian pharmaceutical company focused on developing and commercialising innovative medicines and active pharmaceutical ingredients. Through its wholly owned subsidiary Breathe Life Sciences, it manufactures and distributes controlled substances, including medicinal cannabis, psilocybin and MDMA, across Australia, the UK, Europe and Japan, targeting alternative therapeutics, investigational medicines and consumer health products.
Breathe Life Sciences operates GMP-licensed facilities for manufacturing, warehousing and distribution in Australia, Japan, the UK and Czechia. Its business model centres on final-dose medicine production, contract and white-label manufacturing, wholesale of controlled drugs and APIs, and direct-to-consumer sales under brands such as Dr Watson in multiple international markets.
Average Trading Volume: 2,061,270
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$107.5M
For detailed information about BXN stock, go to TipRanks’ Stock Analysis page.